权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Utilization of Immuno-PET to detect response and guide novel oHSV-based therapy for glioma

利用免疫 PET 检测反应并指导基于 oHSV 的新型神经胶质瘤治疗

基本信息

批准号：
10635507
负责人：
JAMES M MARKERT
金额：
$ 57.14万
依托单位：
UNIVERSITY OF ALABAMA AT BIRMINGHAM
依托单位国家：
美国
项目类别：
财政年份：
2023
资助国家：
美国
起止时间：
2023-04-01 至 2028-03-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10635507
关键词：
Biological Biological Assay Biopsy CD8-Positive T-Lymphocytes CD8B1 gene Cell Cycle Kinetics Cells Characteristics Clinical Combined Modality Therapy Cytolysis Data Disease Progression Dose Flow Cytometry Glioblastoma Glioma Goals Granzyme Heterogeneity Human IL18 gene Image Immune Immune checkpoint inhibitor Immune response ImmunoPET Immunofluorescence Immunologic Immunologic Stimulation Immunologics Immunotherapy Infection Infiltration Inflammation Interleukin-12 Kinetics Knowledge Laboratories Magnetic Resonance Imaging Malignant - descriptor Malignant neoplasm of brain Measures Modeling Molecular Mus Patient Selection Patients Phase I Clinical Trials Positron-Emission Tomography Pre-Clinical Model Prediction of Response to Therapy Proteins Radiation Radiation therapy Regimen Signal Transduction Solid Neoplasm T cell infiltration T cell response T-Cell Activation T-Lymphocyte Testing Therapeutic Tissues Treatment Efficacy Tumor Antigens Tumor Volume Validation Viral Antigens Virus Visualization anti-tumor immune response booster vaccine cell transformation combinatorial imaging modality immune cell infiltrate immunoregulation improved in vivo insight molecular imaging mouse model neoplastic cell novel oncolytic herpes simplex virus pre-clinical predicting response programmed cell death ligand 1 programmed cell death protein 1 quantitative imaging response serial imaging synergism transcriptomics treatment optimization treatment response tumor

项目摘要

PROJECT SUMMARY The overarching goal of this project is to quantify the temporal kinetics of T-cell activation and infiltration during novel combination intratumoral oncolytic herpes simplex virus (oHSV) immunotherapy with advanced molecular immuno- positron emission tomography (PET) imaging in preclinical models of glioblastoma (GBM). Novel targeted oHSV immunotherapy has been shown to directly kill GBM tumor cells as the virus selectively replicates within and lyses malignantly transformed cells, however there is a knowledge gap in understanding the kinetics of the immune cell changes and how to harness those changes to improve therapeutic efficacy. As inflammation and pseudo progression are key characteristics of immunotherapy-induced tumor changes, standard imaging methods fail to provide reliable response assessments, which can sometimes take up to six months to reveal through clinical changes in tumor size. Advanced quantitative imaging strategies can provide spatial and temporal information on biological alterations prior to the clinically observed, downstream changes in tumor size. Immuno- PET imaging could stratify selection of patients who pursue immunotherapy and guide the timing and sequencing of combinatorial therapies. We have preliminary data showing that there are differential responses in CD8 expression in gliomas during oHSV therapy and that oHSV increases CD8 infiltration, as we can image these changes with PET. Further, preliminary evidence shows that granzyme B increases (as measured by GZP-PET) are related to overall tumor response. The overarching hypothesis is PET molecular imaging can guide targeted IL-12 and IL-18 oHSV to enhance therapeutic efficacy and extend survival in preclinical models of GBM. There are three specific aims to answer this hypothesis: Aim 1. Using advanced molecular immunoPET in GBM murine models with biological validation, determine if early T-cell kinetics of infiltration and activation are increased following oHSV therapy alone, or with oHSV expressing IL-12 and/or IL- 18. We will quantify longitudinal alterations in T-cell infiltration with [89Zr]-CD8-PET imaging of CD8+ cells and quantify longitudinal alterations in T-cell activation (granzyme B) with [68Ga]-GZP-PET imaging. Aim 2. Using advanced molecular immunoPET in GBM murine models, determine if secondary therapeutics (radiation therapy, or immunomodulatory immune checkpoint inhibitors) used in combination with oHSV IOT produce increased intermediate term T cell infiltration and activation and improve long-term tumor response. Aim 3. Determine if secondary boosts of oHSV IOT during imaging-identified timing windows of decreased T cell infiltration and activation can salvage therapeutic response. ImmunoPET imaging allows longitudinal quantification of underlying immunological kinetics during oncolytic herpes simplex virus (oHSV) immunotherapy (IOT) that will allow optimization of therapeutic regimens on a personalized basis.

项目总结